<DOC>
	<DOCNO>NCT00309517</DOCNO>
	<brief_summary>This clinical investigation examine influence preoperative radiotherapy combination postoperative 5-fluorouracil + leucovorin chemotherapy vs. 5-fluorouracil + leucovorin + MAb 17-1A chemo-immunotherapy patient â€™ local recurrence rate overall survival time follow surgery rectal carcinoma Dukes B C ( T2-4 , N0-3 , M0 ) .</brief_summary>
	<brief_title>Randomized Study Neoadjuvant Radio-Chemotherapy Rectal Carcinoma Dukes B C</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Patients histologically verify operable rectal cancer Dukes B C ( Stage II , T24 , N03 , M0 ) , R0 Age : 1880 year Karnofsky Performance Status &gt; 80 Adequate bone marrow reserve ( leukocytes &gt; 4,000 , thrombocytes &gt; 105/mm3 , Hb &gt; 10g % ) , renal hepatic function ( total bilirubin creatinine &lt; 1.25 x ULN ) Colon cancer R1 , R2 ; carcinosis peritonei Start treatment &gt; 42 day postop ; adjuvant radiotherapy , chemotherapy immunotherapy Previous application murine chimeric monoclonal antibody antibody fragment Medical therapy steroid , cyclosporin antithymocyte globulin within 3 month prestudy Known hypersensitivity animal protein Serious concomitant disease : HIV , chronically inflammatory intestine , diabetes mell . gravis , cerebral seizure disorder , et al . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2000</verification_date>
	<keyword>Fluorouracil</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>MAb 17-1A</keyword>
	<keyword>Rectal cancer</keyword>
</DOC>